THE CHALLENGE IS PERSONAL

12 Months...average life expectancy for 64% of adults diagnosed with a malignant brain tumor.

Declare
"This is Personal"
by supporting our
cutting-edge research projects!

DONATE NOW
WE DON'T HAVE TIME TO WASTE

The brain cancer community can no longer afford to accept traditional funding models that rely on scheduled requests for proposals, pre-set submission deadlines and 8-12 month review processes. We simply cannot afford to wait for a cure, we must make it happen, and we need your help! Our determination to create impactful projects and serve as frontline explorers in this space comes from not only our professional dedication, but also from our own personal connections.

THIS IS PERSONAL TO US

While our entire staff has been touched by cancer in some way, three of our six team members have been personally impacted by brain cancer. Those personal connections create an environment where passion drives everything we do.


Mark Green

Brain Tumor Survivor

Nike Beddow

Co-Founder, Race for Hope - DC

Danielle Rosenscruggs

Director of Development


THE SCIENCE IS PERSONAL

120...different types of brain tumors. Personalized treatments are a must.

Show that
"This is Personal"
by helping fund
personalized research models!

DONATE NOW
WE ARE LOOKING AHEAD...AND THE FUTURE IS PROMISING

Brain cancer is not a one-size-fits-all disease and our path to treatments can't afford to be either. Our recent projects have demonstrated time and again that a "personalized" approach to research will be crucial in our efforts to find a cure. Genomic sequencing, vaccines and personalized therapeutics are the next evolution in research and we are excited to see these projects move forward.

In order to continue our advance toward a cure, we need your continued support today.

This past year, in partnership with Exosome Diagnostics and the University of California San Diego, we launched the Exosome Diagnostic Tool project. With more than a dozen institutions working together to collect brain tumor, spinal fluid and blood samples we have built the largest, multi-center collaborative the brain tumor community has ever seen. We sat down with Dr. Bob Carter, Chief of Neurosurgery, UCSD Medical Center and the head of the collaborative to hear from him on the promise of a personalized approach:


Dr. Bob Carter, Chief of Neurosurgery, UCSD Medical Center: The Future of Personalized Approaches

OUR APPROACH IS PERSONAL

We know...a cure is possible, and will only be found when many minds work as one.

Show "This is Personal"
and work with us to
find a cure!

DONATE NOW
TOGETHER, WE WILL ACCELERATE THE CURE.

Our mission is to be the catalyst for change in the brain cancer research community and we strive to remain at the forefront of new discoveries.  Thanks to the dedication of our supporters we are able to help engineer exciting projects and facilitate ground-breaking collaborations among academic researchers, biotechnology companies and the pharmaceutical industry. This approach stems from our belief that the path to new treatments will not be discovered by one mind working alone, but rather by many minds working as one. We know you trust us to be brave leaders in the creation of new research and therapeutics and we are proud of our many "firsts" that have pushed progress over the edge and inspired others to follow our lead:


Viewed at the time as a risky and non-traditional application of funding, we became the first brain cancer non-profit to partner with a pharmaceutical company to successfully drive a new drug into the clinic; Avastin became the first new brain cancer drug to be approved in 10+ years.
We were the first non-profit to provide funding for Tocagen, who was able to then go onto raise an additional $85 million in private funding. They currently have the first gene therapy-type of drug for GBM's in clinical trials.
In 2011, we became the first non-profit to partner with Regulus in an effort to expand their research portfolio to include brain cancer. They are now working to develop a microRNA therapeutic to target the "master control switches" in brain tumors.
Prior to our involvement Agios focused exclusively on leukemia research. We provided the support needed to move Agios's cancer metabolism project into brain cancer.  They now have a drug candidate for low grade gliomas moving into the clinic and have gone on to secure a $250 Million strategic partnering investment from Celgene.

STAND WITH US

AND SHOW THAT "THIS IS PERSONAL" TO YOU

Help accelerate the search for new therapeutics and aggressively drive new discoveries into the hands of doctors and patients.